On June 5, 2025, TAG and WHO cohosted a webinar orienting people to long-acting injectables for TB treatment and prevention. Long-acting Injectables (LAIs) have the potential to revolutionize treatment for TB and other infectious diseases. Among long-acting technologies in development for TB, long-acting injectables (LAIs) are the furthest along and beginning to enter early clinical trials.

TAG is partnering with the WHO to gather community perspectives on the preferred characteristics of LAIs for TB to help inform the design and development of LAIs that can meet the needs of people affected by TB. The webinar also launched the Survey on Community Perceptions and Preferences Regarding Long-Acting Injectables for TB Treatment and Prevention.

Facilitators:
Ketho Angami, Global TB CAB

Presenters:

• Samuel Schumacher, Scientist – Global Programme on Tuberculosis & Lung Health, World Health Organization
• Erin McConnell, Senior TB Project Associate, Treatment Action Group
• Nora West, Assistant Professor of Medicine, University of California San Francisco